Use of baicalein as antifungal medicine synergist

An antifungal drug, a technology of baicalein, applied in the field of medicine, can solve the problems such as no reports of baicalein, and achieve the effect of reducing the dosage of drugs

Inactive Publication Date: 2007-11-07
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF0 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] So far, there have been no reports of baicalein as a synergist of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of baicalein as antifungal medicine synergist

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Example 1: Effects of combined use of baicalein and fluconazole on different clinical fungal strains.

[0016] Materials and methods

[0017] 1. Test drug:

[0018] Baicalein: purchased from Sigma.

[0019] Fluconazole: Changzhou No. 2 Pharmaceutical Factory.

[0020] Dimethyl sulfoxide: China Pharmaceutical (Group) Shanghai Chemical Reagent Company.

[0021] Baicalein was formulated with dimethyl sulfoxide to a concentration of 32 mg / ml, and the concentration of fluconazole was 2 mg / ml, and the tested drugs were stored at -20°C. Before the experiment, the drug stock solution was taken out and placed in a 35°C incubator to melt, fully mixed, and the pharmacodynamic test was carried out respectively.

[0022] 2. Strains:

[0023] The clinical strains of Candida albicans, Candida krusei and Microsporum lanoides were provided by the Mycology Department of Shanghai Changhai Hospital. Clinical samples were collected from different departments of the hospital and identif...

Embodiment 2

[0049] Example 2: The effect of baicalein combined with fluconazole on different clinical and laboratory induced drug-resistant strains

[0050] Materials and methods

[0051] 1. Test drug:

[0052] Baicalein: purchased from Sigma.

[0053]Fluconazole: Changzhou No. 2 Pharmaceutical Factory.

[0054] Dimethyl sulfoxide: China Pharmaceutical (Group) Shanghai Chemical Reagent Company.

[0055] Baicalein was formulated with dimethyl sulfoxide to a concentration of 32 mg / ml, and the concentration of fluconazole was 2 mg / ml, and the tested drugs were stored at -20°C. Before the experiment, the drug stock solution was taken out and placed in a 35°C incubator to melt, fully mixed, and the pharmacodynamic test was carried out respectively.

[0056] 2. Strains:

[0057] Clinical drug-resistant strains: Candida albicans were provided by the Fungi Department of Shanghai Changhai Hospital, collected from clinical samples from different departments of the hospital, and identified by m...

Embodiment 3

[0064] Embodiment 3: the combination of baicalein and miconazole, ketoconazole

[0065] Materials and methods

[0066] 1. Test drug:

[0067] Baicalein: purchased from Sigma.

[0068] Miconazole: purchased from China Institute for the Control of Pharmaceutical and Biological Products.

[0069] Ketoconazole: purchased from China Institute for the Control of Pharmaceutical and Biological Products.

[0070] Dimethyl sulfoxide: China Pharmaceutical (Group) Shanghai Chemical Reagent Company.

[0071] Baicalein was formulated with dimethyl sulfoxide to a concentration of 32 mg / ml, miconazole and ketoconazole were formulated with dimethyl sulfoxide to a concentration of 6.4 mg / ml, and the tested drugs were stored at -20°C. Before the experiment, the drug stock solution was taken out and placed in a 35°C incubator to melt, fully mixed, and the pharmacodynamic test was carried out respectively.

[0072] Other experimental steps and methods are the same as in Example 1.

[0073] T...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to medicine technology and is especially new use of baicalein, which is one kind of effective components extracted from skullcap root and has been used in treating various kinds of inflammation, as antifungal medicine synergist. Baicalein is added into antifungal pyrrole medicine in the added amount of 4-16 mcg/ml. Experiments show that adding baicalein into antifungal medicine of fluconazole, ketocanazole, miconazole, etc can ensure the treating effect on fungal inflection and resist the drug tolerance of drug resisting fungi, so that baicalein may be used as the synergist of antifungal medicine.

Description

Technical field: [0001] The invention relates to the technical field of medicine, and relates to the new use of baicalein as a synergist for antifungal drugs. Background technique: [0002] Baicalein (Baicalein, BAI) is one of the active ingredients extracted from the dried root of Scutellaria baicalensis plant of Labiatae. Its structure is shown in formula (I), it is yellow needle-like crystal, and its melting point is 268°C- 272°C (methanol), mainly used in clinical treatment of various acute and chronic inflammations. It has been reported that baicalein has inhibitory effect on Fusarium oxysporum and Candida albicans (Zhou Ligang et al., Antifungal Activity of Flavonoids and Steroids, Natural Product Research and Development, 1997, 3: P24), but its antifungal activity is relatively low. Weak, the required effective drug concentration is higher. [0003] [0004] The azole antifungal drugs include imidazoles and triazoles. In the imidazole group, there are ketoconazo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/352A61K31/4174A61K31/4196A61K31/496A61P31/04
Inventor 曹颖瑛戴宝娣王彦曹永兵朱臻宇徐永刚姜远英
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap